Dr. Persky is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3838 N Campbell Ave
Tucson, AZ 85719Phone+1 520-694-2873Fax+1 520-694-0848- Is this information wrong?
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2000 - 2003
Albert Einstein College of MedicineClass of 2000
Harvard UniversityAB, Biochemical Sciences, Magna Cum Laude, 1992 - 1996
Certifications & Licensure
AZ State Medical License 2002 - 2025
CT State Medical License 2012 - 2014
NY State Medical License 2003 - 2006
MN State Medical License 2001 - 2003
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma Start of enrollment: 2010 Nov 15
- S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma Start of enrollment: 2011 Sep 01
- S9704-S0014-S0313A Studying Genes in Samples From Patients With Limited or Advanced Diffuse Large B-Cell Lymphoma Start of enrollment: 1997 Sep 15
- Join now to see all
Publications & Presentations
PubMed
- A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma.Michael Durando, Ajay K Gopal, Joseph Tuscano, Daniel Persky> ;The Oncologist. 2024 Apr 4
- Optimizing assessment of CD30 expression in Hodgkin lymphoma by controlling for low expression.Shoib Sarwar, Margaret E Tome, Dean Billheimer, Catherine Spier, Catharine L Smith, Daniel Persky, Monika Schmelz> ;Histology and Histopathology. 2024 Mar 1
- 1 citationsExtranodal presentation in limited-stage diffuse large Bcell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001.Deborah M Stephens, Hongli Li, Louis S Constine, Thomas J Fitzgerald, John P Leonard, Brad S Kahl, Joo Y Song, Michael L LeBlanc, Sonali M Smith, Daniel O Persky, Jona...> ;Haematologica. 2022 Nov 1
- Join now to see all
Journal Articles
- Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma (L-NN-MCL) with P53 Gene Re-arrangement/Mutation Is Highly Responsive to Rituximab/Ibrutinib Combination TherapyShahram Mori, Juan Varela, Steven C Goldstein, Daniel O Persky, Clinical Lymphoma, Myeloma, & Leukemia
- Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/vincristine in Relapsed/refractory Aggressive B-cell LymphomaDaniel Persky, Soham Puvvada, Catherine Spier, Gregory Monohan, Ari VanderWalde, Daruka Mahadevan, Clinical Cancer Research
Abstracts/Posters
- The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated ...Daniel O. Persky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)Daniel O. Persky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- SYK Inhibitor Entospletinib in Combination with Obinutuzumab Demonstrates Efficacy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)Daniel O. Persky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Authored Content
- Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma (L-NN-MCL) with P53 Gene Re-arrangement/Mutation Is Highly Responsive to Rituximab/Ibrutinib Combination TherapyNovember 2018
Press Mentions
Clinical Challenges: Using MRD in Chronic Lymphocytic Leukemia ManagementDecember 22nd, 2021- Many Non-Hodgkin's Lymphoma Patients Can Skip Radiation, Collaborative Study FindsOctober 6th, 2020
Study: Most with Early DLBCL Can Skip RTDecember 9th, 2019
Grant Support
- 2014 Cancer Clinical Investigator Team Leadership AwardNCIPresent
Committees
- Member, SWOG Lymphoma Working Committee
Professional Memberships
- Member
- Member
Hospital Affiliations
Banner - University Medical Center TucsonTucson, Arizona
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
